Another insurance company continues to rate the WVU Cancer Institute Osborn Hematopoietic Malignancy and Transplantation Program as excellent. Highmark Blue Cross Blue Shield in West Virginia recently notified the program that it has received the company’s Blue Distinction Centers for Transplants Designation, which denotes commitment to delivering quality specialty care safely, effectively and cost efficiently. This marks the second consecutive time the Cancer Institute has received the designation from Highmark. “This validates that our program continues to provide superior care,” Sonia Leadmon, oncology quality coordinator at the Cancer Institute Mary Babb Randolph Cancer Center, said.
The health insurer took into consideration patient volume, transplant quality outcomes and additional accreditations the program has previoulsly received from other agencies.
The WVU Cancer Institute will hold its Annual DeLynn Lecture with Maura L. Gillison, MD, PhD, who will lecture on HPV and the Host Genome, at 4 pm on Tuesday, Sept. 4, in the WVU Health Sciences Center's Fukushima Auditorium (room 1901). A Q&A session will follow the lecture. The event is free and open to the public. For those who cannot attend, the event also will be webcast.
Four WVU Medicine hospitals have been recognized by U.S. News & World Report as part of its 2018-19 Best Hospitals in the United States.
The WVU School of Public Health will kick off its 2018-2019 Dean’s Colloquium Series with a discussion about the future of public health education.